Taking A Digital Therapeutics Company Public Via A SPAC

Source: Life Science Leader

David Perry, chairman and cofounder Better Therapeutics, a digital therapeutics company, provides an overview of what is a special purpose acquisition company (SPAC), and the approach to determine that this, combined with a private investment in public equity (PIPE) was the right fit for taking his company public this year. An explanation around some of the pros and cons of SPACs finds Tom Frohlich, CBO of Chinook Therapeutics, joining the conversation.